Biotechnology company QLT has announced to acquire Aegerion Pharmaceuticals through its wholly-owned, indirect subsidiary Isotope Acquisition Corp (MergerCo.) to diversify its portfolio of commercialised rare disease programmes.

Pursuant to the acquisition, Isotope Acquisition Corp (MergerCo.) will be merged into Aegerion Pharmaceuticals and serve as a wholly-owned, indirect subsidiary of QLT, which will further be renamed as Novelion Therapeutics.

Greenhill & Co is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal advisor to the acquirer, while JP Morgan Chase & Co is acting as financial advisor and Ropes & Gray LLP is acting as legal advisor to the target company for the transaction.

Carbylan Therapeutics has entered a definitive share purchase agreement to acquire KalVista Pharmaceuticals.

"Carbylan Therapeutics has entered a definitive share purchase agreement to acquire KalVista Pharmaceuticals."

According to the agreement, Carbylan Therapeutics will be renamed as KalVista Pharmaceuticals and, following the transaction, the existing equity holders of KalVista Pharma will own approximately 81% of the combined company, whereas Carbylan Therapeutics shareholders will own the remaining.

Wedbush PacGrow Life sciences is acting as the advisor and Latham & Watkins LLP is acting as the legal advisor to Carbylan Therapeutics, while Jefferies LLC is acting as advisor and Fenwick & West LLP and Cooley LLP are acting as legal advisors to KalVista Pharma for the transaction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will enable KalVista Pharma to advance the development of its plasma Kallikrein inhibitor platform, hereditary angioedema (HAE) and diabetic macular oedema (DME) programmes and provide patients with much needed treatment.